Denmark’s Orphazyme files to go public on Nasdaq

/ / News

Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer. The biopharmaceutical company’s stock currently trades on Nasdaq Copenhagen, and trades in the U.S. over-the-counter. The company expect its stock to trade on the Nasdaq exchange under the ticker symbol “ORPH.” The joint book-running managers are BofA Securities, Cowen and Guggenheim Securities. For the six months ended June 30, the company recorded a net loss of $37.93 million on no revenue, after a loss of $163.9 million on no revenue in the year-ago period. The company harnesses heat shock proteins to develop treatments of neurodegenerative orphan diseases. The company is looking to trade publicly in the U.S. during a good year for IPOs, as the Renaissance IPO ETF has soared 48.6% year to date while the S&P 500 has gained 5.4%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.